Strategic financing from Oaktree Capital Management and Omar’s Life Sciences is expected to support the U.S. launch of Verona’s promising chronic obstructive pulmonary disease treatment, ensifentrine.
Verona Pharma receives $650 million investment from Oaktree Capital Management and OMERS Life Sciences
Leave a comment
